Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive…
- 60% response rate observed among 10 evaluable patients - Favorable safety profile in 26 patients enrolled as of the…
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in…
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO…
Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other…
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)HOUSTON, May…
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
Additional clinical and real-world data from the industry’s largest and broadest amyloidosis pipeline will advance understanding of underlying mechanisms of…
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National…
The company is radically redefining the care model for cancer survivorship BOSTON, MA / ACCESSWIRE / May 23, 2024 /…